Interleukin 4
Interleukin 4
Overview
Interleukin 4 (IL-4) is a pleiotropic cytokine of the immune system with a central role in type 2 immune responses. It is produced by activated T cells and other immune cells and acts through the IL-4 receptor to influence leukocyte differentiation, antibody class switching, and inflammatory signaling. Biologically, IL-4 is best known for promoting T helper 2-associated responses and for driving macrophage polarization toward an alternatively activated, anti-inflammatory M2 phenotype.
In biomedical research, IL-4 is frequently studied as both a disease-associated biomarker and a therapeutic modulator. Its activity is relevant to allergic inflammation, asthma, atopic dermatitis, and other Th2-skewed conditions, but it is also investigated in regenerative medicine because of its immunoregulatory effects. Recent studies have used IL-4 in hydrogel and biomaterial systems, in combination with pathways such as NF-κB/IκB, PI3K/AKT/HIF-1α, and with inflammatory mediators including IL17A, IL-13, and TNF-α, reflecting its broad role at the interface of immunity, tissue repair, and chronic inflammation.
Focus of Latest Publications
Recent publications have continued to position IL-4 as a key regulator of inflammation, tissue repair, and disease-associated immune remodeling. In osteoporosis research, targeted IL-4 nanoparticles were developed to modulate osteal macrophages, reflecting the cytokine’s known ability to suppress osteoclast differentiation and influence macrophage fate in bone-resorptive environments. This line of work links IL-4 to bone homeostasis and suggests that local delivery strategies may be useful for shifting macrophage behavior toward a reparative phenotype.
Several studies focused on IL-4 in macrophage polarization and tissue repair. In a polycystic ovary syndrome model induced by dehydroepiandrosterone, IL-4 was reported to ameliorate ovarian histopathological changes and restore ovulatory function by promoting M2 macrophage polarization through the NF-κB/IκB pathway. In renal repair research, an IL-4 peptide hydrogel was used to reprogram mesenchymal stem cell heterogeneity toward a CD106+ population with enhanced regenerative and immunomodulatory properties. Similarly, dual-function hydrogel microspheres co-loaded with IL-4 and chitosan-BSA nanoparticles encapsulating calcitonin gene-related peptide were designed to coordinate immune regulation and osteogenesis coupling in femoral regeneration.
IL-4 also appeared in studies of inflammatory disease biomarkers and immune profiling. A plasma protein signature study for cerebral amyloid angiopathy included IL4 among the biomarkers that, together with C-reactive protein, C-C motif chemokine ligand 11, neuropeptide Y, and PDLIM5, improved diagnostic discrimination. In a recent-onset type 1 diabetes cohort, IL4 release from CD8+ T cells was inversely associated with hepatic lipid content, alongside IL-2, IL-13, and TNF release, suggesting broader links between cytokine output and metabolic state. In a pilot study of electroacupuncture for chronic nonspecific low back pain, IL-4 levels decreased after treatment, accompanied by an increase in IL-10 and a reduction in interferon-gamma, indicating measurable short-term effects on inflammatory markers.
Multiple studies used IL-4 as a readout of type 2 inflammation or treatment response in allergic and airway disease. In allergic rhinitis, a dual-action nasal spray containing mussel protein and xylitol attenuated type 2 inflammation in human nasal epithelial cells stimulated with lipopolysaccharide, reducing IL-4, IL-5, and IL-13 release while restoring epithelial barrier proteins. In atopic dermatitis research, chlorophytum borivilianum was associated with downregulation of IL-4, IL-6, IL-13, and TNF-α gene expression, while a phthalazinone PARP14 inhibitor reduced skin lesions and decreased IL-4, IL-13, IgE, and IL-17A expression, showing efficacy comparable to or better than upadacitinib and RBN-3143 in the reported model. Another atopic dermatitis study using kaempferol-loaded solid lipid nanoparticles found upregulation of IL-4 and IL-10 alongside suppression of IL-1β, TNF-α, COX-2, MMP-13, IL-17A, and IL-33, consistent with an anti-inflammatory shift in arthritic tissue. In a separate context, IL-4 was also measured as part of inflammatory cytokine panels in renal dysfunction, acute liver failure, and septic arthritis studies.
IL-4 remains important in vaccine and infectious disease immunology as well. A novel intranasal nano-adjuvanted pertussis vaccine in a rodent model induced strong IgG and secretory IgA responses and increased IFN-γ, IL-4, and IL-17, indicating balanced humoral and cellular immune activation. In cystic fibrosis research, exposure of epithelia to IL-4 markedly amplified rescue of nonsense-mutant CFTR chloride channel function under inflammatory conditions, highlighting the cytokine’s ability to alter epithelial biology and drug responsiveness. Across these studies, IL-4 is consistently treated as both a mechanistic mediator and a biomarker of immune polarization.
Therapeutically, IL-4 signaling is also relevant because it is targeted by dupilumab, a monoclonal antibody that downregulates interleukin-4, interleukin-13, and the T helper 2 cell pathway. Recent reports discussed its use in pregnancy and in pediatric liver transplant recipients with eosinophilic esophagitis and atopic dermatitis, emphasizing ongoing clinical interest in IL-4 pathway blockade.